Cristina Calviño-Suarez

Cristina Calviño-Suarez

Auto-generated profile, based on publicly available information

Cristina Calviño-Suarez

Gastroenterology Department, University Hospital of Santiago de Compostela, A Coruña, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
WHWei Huang
Wei Huang
JIJulio Iglesias-Garcia
Julio Iglesias-Garcia
IBIria Baston-Rey
Iria Baston-Rey
CCCristina Calviño-Suarez
Cristina Calviño-Suarez
JLJose Lariño-Noia
Jose Lariño-Noia
RSRobert Sutton
Robert Sutton
The epidemiology of exocrine pancreatic insufficiency (EPI) after acute pancreatitis (AP) is uncertain. We sought to determine the prevalence, progression, etiology and pancreatic enzyme replacement therapy (PERT) requirements for EPI during follow-up of AP by systematic review and meta-analysis.

22 October 2018 in Helicobacter
Verified
Journal Article
Open access
PDF file
FMFernando Macías‐García
Fernando Macías‐García
IBIria Bastón‐Rey
Iria Bastón‐Rey
JIJulio Iglesias-Garcia
Julio Iglesias-Garcia
CCCristina Calviño‐Suárez
Cristina Calviño‐Suárez
LNLaura Nieto‐García
Laura Nieto‐García
JDJuan Enrique Domínguez‐Muñoz
Juan Enrique Domínguez‐Muñoz
Background: Concomitant quadruple (CQT) or bismuth‐containing quadruple therapy (BQT) is recommended as first‐line treatment for Helicobacter pylori infection depending on antibiotic resistance.Aim: To compare the efficacy, safety, and compliance of CQT and BQT as first‐line therapy for H. pylori eradication in real clinical practice in an area of high resistance to clarithromycin.Methods: A prospective, open, comparative cross‐sectional study including dyspeptic patients >18 years with H. pylori infection and with no previous eradication treatment was performed. CQT (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g + metronidazole 500 mg, all given twice daily, for 14 days) or BQT (omeprazole 20 mg twice daily + 3 capsules of Pylera® 4 times a day, for 10 days) was prescribed at the discretion of the prescribing physician. Eradication was tested by 13C‐urea breath test. Efficacy was assessed by intention‐to‐treat (ITT) and per‐protocol (PP) analyses.Results: One hundred and four consecutive patients were included (64.4% female, age 52.9 years). Fifty patients received CQT and 54 BQT. Eradication rate was similar with both therapies at the PP (CQT 97.9%, 95% CI: 93.9‐100 vs BQT 96.2%, 95% CI: 90.9‐100, P = 0.605) and ITT analyses (CQT 98.0%, 95% CI: 94‐100 vs BQT 94.4%, 95% CI: 88.1‐100, P = 0.346). The rate of adverse events was also similar with CQT (56%) and BQT (46.3%). One patient in each group discontinued the treatment due to significant adverse events.Conclusion: The use of CQT and BQT as first‐line treatment against H. pylori is similarly effective and safe strategy in an area of high clarithromycin resistance.

1 April 2020 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
MAManuel Barreiro-de Acosta
Manuel Barreiro-de Acosta
IBIria Bastón‐Rey
Iria Bastón‐Rey
CCCristina Calviño‐Suárez
Cristina Calviño‐Suárez
JDJ Enrique Domínguez‐Muñoz
J Enrique Domínguez‐Muñoz
Pouchitis is a frequent complication in ulcerative colitis patients after proctocolectomy with ileal pouch–anal anastomosis. It is an unspecific inflammation of the pouch with unknown aetiology. First‐line treatment for acute and chronic pouchitis is antibiotics. Some cases of severe chronic refractory pouchitis may benefit from biological treatment. Anti‐tumour necrosis factor should be recommended as the first option, leaving the new biologicals for multirefractory patients. Permanent ileostomy may be an option in severe cases, after failure of medical treatment. Prophylaxis therapy with a probiotic mixture is recommended after the first episode of pouchitis, whereas it is not clear whether probiotics are useful for all patients after surgery. Here, we present a case report and review the treatment options in different forms of pouchitis.

1 August 2020 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
IBIria Bastón-Rey
Iria Bastón-Rey
CCCristina Calviño-Suarez
Cristina Calviño-Suarez
MAManuel Barreiro-De Acosta
Manuel Barreiro-De Acosta


1 September 2019 in Pancreatology
Verified
Journal Article
Closed access
JIJulio Iglesias-Garcia
Julio Iglesias-Garcia
EME. Martínez Moneo
E. Martínez Moneo
RFR. Mejuto Fernández
R. Mejuto Fernández
NMN. Gendive Martín
N. Gendive Martín
VBV. Mauriz Barreiro
V. Mauriz Barreiro
JMJ.E. Domínguez Muñoz
J.E. Domínguez Muñoz